MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss
-$4,031,486
(-3600.21%↓ Y/Y)
Net loss
-$4,023,640
(-835.33%↓ Y/Y)
Total other
comprehensive income (gain)
-$7,846
(-102.44%↓ Y/Y)
Net Income Loss
-$3,091,394
(-618.62%↓ Y/Y)
Deemed dividend
$932,246
Unrealized foreign
currency translation...
-$7,846
(-102.44%↓ Y/Y)
Change in fair value of
warrant liability
-$593,710
Change in fair value of
derivative liabilities
$87,728
(545.96%↑ Y/Y)
Gain (loss) on
extinguishment of debt, net
$14,317
(176.32%↑ Y/Y)
Interest income
$37
Loss before taxes
-$3,091,394
(-618.62%↓ Y/Y)
Total other income
(expense), net
$563,340
(359.84%↑ Y/Y)
Interest expense
$58,955
(-50.43%↓ Y/Y)
Other expense
$54,000
Foreign currency
transaction gain (loss)
-$19,497
(76.82%↑ Y/Y)
Loss from operations
-$3,654,734
(-1612.77%↓ Y/Y)
Total operating
expenses
$3,654,734
(1612.77%↑ Y/Y)
Administration expenses
$3,628,173
(2262.20%↑ Y/Y)
Research and development
$19,961
(-63.30%↓ Y/Y)
Occupancy expenses -
related party
$6,600
(22.20%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)